Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13290604 | 0.73 | KDM4E (0.35) | MMP9MMP13MMP1 | |
| SCHEMBL15447118 | 0.72 | MAOB (0.36) | MAOBMMP2MMP9MMP13MMP1 | |
| SCHEMBL24247404 | 0.71 | LMNA (0.40) | MAOBBCHEMAOA | |
| SCHEMBL1769287 | 0.71 | — | — | |
| SCHEMBL26831741 | 0.71 | LMNA (0.40) | MAOBBCHEMAOA | |
| SCHEMBL15870032 | 0.71 | LMNA (0.40) | MAOBBCHEMAOA | |
| SCHEMBL31673192 | 0.68 | BCHE (0.32) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL20857095 | 0.67 | DRD2 (0.36) | MAOBDRD2SIGMAR1MAOA | |
| SCHEMBL27498560 | 0.67 | BCHE (0.51) | MAOBBCHEMAOA | |
| SCHEMBL2475455 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1182123-C | Substituted bicyclic derivatives useful as anticancer agents | �Ʒ� | 2004-12-29 | — | — | CN | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | MAOB 2762/4885MMP2 2676/4885MMP9 3920/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | MAOB 2762/4885MMP2 2676/4885MMP9 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.